MINISTRY-FOREIGN-JAPAN
29.2.2024 14:19:31 CET | Business Wire | Press release
On February 19th, representatives of the governments of Japan and Ukraine, as well as business organizations, gathered in Tokyo for the Japan-Ukraine Conference for Promotion of Economic Growth and Reconstruction.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229458562/en/
Prime Minister Kishida Fumio emphasized how Japan can contribute to Ukraine’s post-war reconstruction. (Photo by: Cabinet Public Affairs Office)
The Japanese government delegation, led by Prime Minister of Japan Kishida Fumio, pledged long-term support for Ukraine's recovery through public-private partnership. The Ukrainian delegation, led by Prime Minister of Ukraine Denys Shmyhal, thanked Japan for its assistance and invited Japanese businesses to invest in Ukraine's reconstruction. Each delegation consisted of more than 100 government and corporate officials. In total, around 300 people and 130 companies took part in the conference. The two governments agreed to cooperate on seven key areas: land mine action and debris clearance, humanitarian aid and livelihood reconstruction, agricultural development, biotechnology, digital and information technology, transportation and energy infrastructure, and anti-corruption and governance-strengthening measures.
In his keynote speech, Prime Minister Kishida described supporting Ukraine's recovery from the ongoing war as "investing in the future," and called on the international community to contribute. “Japan’s public and private sectors will all work together through an all-Japan approach, utilizing the knowledge derived from Japan’s postwar and disaster reconstruction efforts,” he said in his speech. “The promotion of economic reconstruction, however, is not only investment for the future of Ukraine but also investing in Japan and the whole globe.” He outlined new initiatives for Japan's public and private sectors to support Ukraine. Kishida also announced that Japan would ease entry visa requirements for Ukrainian citizens involving in Japan-Ukraine cooperation projects.
Prime Minister Shmyhal thanked Japan for its ongoing assistance and Prime Minister Kishida for his visit to Ukraine in 2023. He added “Today’s conference will be the next step towards continuing the development of both countries’ relationships.” Shmyhal mentioned the financial success of Japanese companies in Ukraine so far and invited businesses to further invest in the coming “Ukrainian economic miracle.” He underlined key sectors such as energy, agriculture, and infrastructure as offering prime investment opportunities with robust growth potential.
Both leaders emphasized their commitment to cooperation, as well as the importance of the private sector in Ukraine's reconstruction.
The conference resulted in the announcement of 56 documents, including inter-governmental agreements. The two governments signed a convention eliminating double taxation, which will support Japanese companies to invest in Ukraine. They also signed an agreement on bilateral crediting, exchanged notes concerning a grant aid for emergency recovery, and pledged to collaborate in the fields of education and technology.
Other documents included deals between government agencies and individual businesses and business organizations. Japanese companies signed deals with Ukrainian companies and government agencies to develop energy facilities, rebuild infrastructure, remove land mines, and more.
Since the Russian invasion in February 2022, Japan has consistently provided humanitarian aid and other assistance to Ukraine. With the public-private partnership announced at this conference, Japan plans to use its technological expertise and experience in post-disaster recovery and reconstruction to strengthen its support for Ukraine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229458562/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom